PT  - JOURNAL ARTICLE
AU  - Małgorzata Farnik
AU  - Karolina Zawada-Drozd
AU  - Adam Barczyk
TI  - Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
AID  - 10.1183/13993003.congress-2021.PA882
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA882
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA882.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA882.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: The administration of biological therapies exclusively in the hospital became problematic with the onset of the pandemic. To avoid treatment discontinuation, patients were switched into home-administration therapy.Aim of the study: The aim of study was to assess asthma control and quality of life in patients who continued biological therapy in the module of home-administration. Patients’ attitudes towards home treatment and their concerns about COVID-19 were also analyzed.Material and methods: A single-center, prospective analysis of 29 patients treated with biologics for severe asthma, who switched from hospital treatment to home treatment with the onset of the COVID-19 pandemic in Poland. After 3 months a control visit took place in the hospital. Asthma Control Test - ACQ and mini Asthma Quality of Life Questionnaire - miniAQLQ were assessed before and after 3 months of home-use, patients were completing short questionnaire assessing their attitudes towards home treatment and COVID concern scale (CCS), which was developed for this study.Results: ACQ didn’t show statistical differences if compared before(mean 2.5 SD 1.2) and after next 3 months of home-administration(mean 2.1 SD 1.1); p=0.3. Mini AQLQ didn’t show significant differences before (mean 4.1 SD 1.2) and after next 3 months of home-use (mean 4.5 SD 1.1) p=0,2. Nearly all respondents (93.1%) had worried about bad prognosis if the case of COVID-19, and 51,7% were afraid to die. Most patients (79.3%) had declared home-administration as preferred.Conclusions: Patients switched to home-administration didn’t show any deterioration of asthma control and HRQoL.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA882.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).